UnknownPHASE1, PHASE2NCT05708950
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Studying Gonadal germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kineta Inc.
- Principal Investigator
- Thierry Guillaudeux, PhDKineta Inc.
- Intervention
- KVA12123 - Dose Escalation(drug)
- Enrollment
- 314 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2024
Study locations (6)
- UCLA Health (Santa Monica Cancer Care), Santa Monica, California, United States
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
- Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota, Florida, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05708950 on ClinicalTrials.govOther trials for Gonadal germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07318051Sample Collection for Ongoing Research and Product Evaluation StudyNatera, Inc.
- RECRUITINGNCT05645510LIVInG With chrONic Cancer TrEatments (LONGEVITI) StudyUniversity of Alberta
- RECRUITINGNANCT05142982Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced SeminomaTata Memorial Centre
- RECRUITINGNANCT05053230A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With CancerMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT04752826BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)BioInvent International AB
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04205227ENB003 Plus Pembrolizumab Phase 1b/2a in Solid TumorsENB Therapeutics, Inc
- ACTIVE NOT RECRUITINGPHASE1NCT03872947A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsToray Industries, Inc
- RECRUITINGNANCT03787056Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer PatientsHospices Civils de Lyon